clinical trial · NCT06623422
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 680
Carcinoma, Non-Small-Cell LungPembrolizumabCisplatinCarboplatinPemetrexedGemcitabinePaclitaxelIntismeran autogenePlacebo
brief summary
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
started
Oct 21, 2024
primary completion
May 16, 2033
completion
Jan 26, 2038
last updated
May 4, 2026
official title
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol